Literature DB >> 25388608

Body dysmorphic disorder and olfactory reference disorder: proposals for ICD-11.

David Veale1, Hisato Matsunaga2.   

Abstract

The article reviews the historical background and symptoms of body dysmorphic disorder (BDD) and olfactory reference disorder, and describes the proposals of the WHO ICD-11 Working Group on the Classification of Obsessive-Compulsive and Related Disorders related to these categories. This paper examines the possible classification of BDD symptoms in ICD-10. Four different possible diagnoses are found (hypochondriacal disorder, schizotypal disorder, delusional disorder, or other persistent delusional disorder). This has led to significant confusion and lack of clear identification in ICD-10. Olfactory reference disorder can also be classified as a delusional disorder in ICD-10, but there is no diagnosis for non-delusional cases. The Working Group reviewed the classification and diagnostic criteria of BDD in DSM-5, as well as cultural variations of BDD and olfactory reference disorder that include Taijin Kyofusho. The Working Group has proposed the inclusion of both BDD and olfactory reference disorder in ICD-11, and has provided diagnostic guidelines and guidance on differential diagnosis. The Working Group's proposals for ICD-11 related to BDD and olfactory reference disorder are consistent with available global evidence and current understanding of common mechanisms in obsessive-compulsive and related disorders, and resolve considerable confusion inherent in ICD-10. The proposals explicitly recognize cultural factors. They are intended to improve clinical utility related to appropriate identification, treatment, and resource allocation related to these disorders.

Entities:  

Mesh:

Year:  2014        PMID: 25388608     DOI: 10.1590/1516-4446-2013-1238

Source DB:  PubMed          Journal:  Braz J Psychiatry        ISSN: 1516-4446            Impact factor:   2.697


  6 in total

1.  Innovations and changes in the ICD-11 classification of mental, behavioural and neurodevelopmental disorders.

Authors:  Geoffrey M Reed; Michael B First; Cary S Kogan; Steven E Hyman; Oye Gureje; Wolfgang Gaebel; Mario Maj; Dan J Stein; Andreas Maercker; Peter Tyrer; Angelica Claudino; Elena Garralda; Luis Salvador-Carulla; Rajat Ray; John B Saunders; Tarun Dua; Vladimir Poznyak; María Elena Medina-Mora; Kathleen M Pike; José L Ayuso-Mateos; Shigenobu Kanba; Jared W Keeley; Brigitte Khoury; Valery N Krasnov; Maya Kulygina; Anne M Lovell; Jair de Jesus Mari; Toshimasa Maruta; Chihiro Matsumoto; Tahilia J Rebello; Michael C Roberts; Rebeca Robles; Pratap Sharan; Min Zhao; Assen Jablensky; Pichet Udomratn; Afarin Rahimi-Movaghar; Per-Anders Rydelius; Sabine Bährer-Kohler; Ann D Watts; Shekhar Saxena
Journal:  World Psychiatry       Date:  2019-02       Impact factor: 49.548

Review 2.  Olfactory Reference Disorder: Diagnosis, Epidemiology and Management.

Authors:  Eileen Thomas; Stéfan du Plessis; Bonginkosi Chiliza; Christine Lochner; Dan Stein
Journal:  CNS Drugs       Date:  2015-12       Impact factor: 5.749

3.  Sniffing out olfactory reference syndrome.

Authors:  Eileen Thomas; Juané Voges; Bonginkosi Chiliza; Dan J Stein; Christine Lochner
Journal:  S Afr J Psychiatr       Date:  2017-01-31       Impact factor: 1.550

Review 4.  Comorbidity between obsessive-compulsive disorder and body dysmorphic disorder: prevalence, explanatory theories, and clinical characterization.

Authors:  Álvaro Frías; Carol Palma; Núria Farriols; Laura González
Journal:  Neuropsychiatr Dis Treat       Date:  2015-08-26       Impact factor: 2.570

Review 5.  Recent advances in understanding and managing body dysmorphic disorder.

Authors:  Georgina Krebs; Lorena Fernández de la Cruz; David Mataix-Cols
Journal:  Evid Based Ment Health       Date:  2017-07-20

6.  Empirically defining treatment response and remission in body dysmorphic disorder.

Authors:  Lorena Fernández de la Cruz; Jesper Enander; Christian Rück; Sabine Wilhelm; Katharine A Phillips; Gail Steketee; Suraj Sarvode Mothi; Georgina Krebs; Laura Bowyer; Benedetta Monzani; David Veale; David Mataix-Cols
Journal:  Psychol Med       Date:  2019-10-30       Impact factor: 7.723

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.